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Abstract
Purpose—This study examined the clinical significance of switching from olanzapine,
quetiapine, or risperidone to aripiprazole by examining changes in predicted risk of cardiovascular
disease (CVD) according to the Framingham Risk Score (FRS) and metabolic syndrome status.
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FRS estimates 10-year risk of “hard” coronary heart disease (CHD) outcomes (myocardial
infarction and coronary death) while metabolic syndrome is associated with increased risk of
CVD, stroke, and diabetes mellitus.
Method—Changes in FRS and metabolic syndrome status were compared between patients with
BMI ≥ 27 and non-HDL-C ≥ 130 mg/dL randomly assigned to stay on stable current treatment
(olanzapine, quetiapine, or risperidone) or switch to treatment with aripiprazole with 24 weeks of
follow-up. All study participants were enrolled in a behavioral program that promoted healthy diet
and exercise.
Results—The pre-specified analyses included 89 switchers and 98 stayers who had post-baseline
measurements needed to assess changes. Least squares mean estimates of 10-year CHD risk
decreased more for the switch (from 7.0% to 5.2%) than the stay group (from 7.4% to 6.4%)
(p=0.0429). The odds ratio for having metabolic syndrome (stay vs. switch) at the last observation
was 1.748 (95% CI 0.919, 3.324, p=0.0885).
Conclusion—Switching from olanzapine, quetiapine, or risperidone to aripiprazole was
associated with larger reductions in predicted 10-year risk of CHD than the behavioral program
alone. The advantage of switching on metabolic syndrome was not statistically significant. The
benefits of switching must be balanced against its risks, which in this study included more
discontinuations of the study treatment but no significant increase in symptoms or hospitalizations.
Keywords
Antipsychotics; Metabolic side effects; Randomized clinical trial
1. Introduction
The average life expectancy among individuals with schizophrenia in the U.S. is 61 years
compared to 76 years for the general population, representing a 20% reduced life expectancy
(Hennekens, Hennekens et al. 2005). A major cause of premature death in schizophrenia is
cardiovascular disease (CVD)(Osby, Correia et al. 2000; Hennekens, Hennekens et al. 2005;
Bushe, Taylor et al. 2010). Many factors, including high rates of smoking, sedentary
lifestyle, unhealthy diet, and a high prevalence of frequently untreated (Nasrallah, Meyer et
al. 2006) hypertension and metabolic problems (obesity, dyslipidemia, and insulin
resistance) contribute to the increased risk of CVD in patients with schizophrenia. In
addition, antipsychotics are associated with varying degrees of adverse metabolic effects.
For example, chlorpromazine, clozapine, olanzapine, quetiapine, and risperidone are
associated with substantial weight gain and adverse metabolic effects, while aripiprazole,
fluphenazine, haloperidol, ziprasidone and some newer antipsychotics have less prominent
effects on these measures (Allison, Mentore et al. 1999; Newcomer 2005; Citrome 2011).
The Framingham Risk Score (FRS), derived from the Framingham Heart Study (Wilson,
D’Agostino et al. 1998) is a clinically useful and widely used way to predict risk of coronary
heart disease, including cardiac death, myocardial infarction, and angina. The FRS is a
function of sex, age, HDL cholesterol, total cholesterol, systolic blood pressure, and
presence of smoking. This risk score has been validated in several populations, and was used
in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia
study to demonstrate that individuals with schizophrenia had higher predicted CHD risk than
matched controls from the general population (Goff, Sullivan et al. 2005). Additional
analyses showed that the antipsychotic drugs studied in CATIE were associated with
substantially different predicted 10-year risks of CHD (Daumit, Goff et al. 2008).
Metabolic syndrome is a clustering of several cardiovascular risk factors including central
adiposity, hyperglycemia, dyslipidemia and hypertension (2002) and is another common
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approach to assess risk of cardiovascular disease—individuals with metabolic syndrome are
at increased risk of CVD compared to those without metabolic syndrome. The intended use
of the metabolic syndrome diagnosis is to identify individuals at risk of CVD and to initiate
interventions to decrease the risk of premature mortality from cardiovascular disease.
Metabolic syndrome, however, has been criticized as having an arbitrary number of criteria
and unvalidated thresholds for meeting each of the criteria (Reaven 2005). In addition,
metabolic syndrome is less accurate than the FRS in predicting CVD (Reaven 2011).
Nevertheless, metabolic syndrome is widely understood as a marker of increased risk of
CVD. Analyses from the CATIE trial demonstrated that the prevalence of metabolic
syndrome in persons with chronic schizophrenia is much higher than matched controls from
the general population (McEvoy, Meyer et al. 2005).
In this paper we examine the impact on the risk of cardiovascular disease, as measured by
the FRS and metabolic syndrome, of switching from widely used antipsychotics that are
known to be associated with adverse weight and metabolic effects (olanzapine, quetiapine,
and risperidone) to treatment with aripiprazole, which is associated with a lower rate of such
effects (2004; Newcomer 2005). The results of the primary and key secondary outcomes of
the study, change in non-HDL cholesterol and efficacy failure, respectively, were previously
published (Stroup, McEvoy et al. 2011).
2. Method
The Comparison of Antipsychotics for Metabolic Problems (CAMP) study is a multi-site
randomized controlled clinical trial conducted between January 2007 and March 2010 at 27
clinical research centers affiliated with the Schizophrenia Trials Network (STN) in the U.S.
(Stroup, McEvoy et al. 2011). Study participants were individuals with schizophrenia or
schizoaffective disorder judged to be clinically stable on treatment with olanzapine,
quetiapine, or risperidone, and who were at increased risk for cardiovascular disease as
indicated by an elevated body-mass index (BMI) ≥ 27 and a non-HDL-C ≥ 130 mg/dl (if
non-HDL-C was 130 to 139, then LDL cholesterol was required to be ≥ 100 mg/dl). Patients
with diabetes (fasting blood glucose ≥ 126 mg/dl or treated with insulin or an oral
hypoglycemic drug) and severe dyslipidemias (non-HDL-C >300 mg/dl or triglycerides >
500 mg/dl) were excluded because the study purpose was to examine whether switching
could prevent such serious metabolic problems. Patients with a history of cardiovascular
disease or cerebrovascular disease were excluded. Patients were treated with the qualifying
drug for a minimum of three months and without dosage adjustments or the adjunctive use
of any other antipsychotic medication for at least one month prior to enrollment. All
participants provided written informed consent that was approved by the Institutional
Review Board (IRB) of the participating sites. Patients were randomly assigned on a 1:1
basis to switch to aripiprazole or to stay on their current antipsychotic medication.
Treatment assignment (stay vs. switch) was stratified by antipsychotic medication taken
when entering the study (olanzapine, quetiapine, and risperidone). Individuals assigned to
stay on the current antipsychotic treatment remained on the pre-study dosage with
adjustments only as clinically indicated within allowed ranges. The allowed dosages were:
olanzapine 5–20 mg daily, quetiapine 200–1200 mg daily, and risperidone 1–16 mg daily.
Patients assigned to switch to aripiprazole began taking aripiprazole 5 mg daily and
continued their previous antipsychotic medication and dose for one week. Over the next 3
weeks the dosage of aripiprazole was gradually increased while the previous medication was
tapered off. After 4 weeks the allowed dosage range for aripiprazole was 5–30 mg daily.
Treatment was open-label but raters blinded to treatment assignment conducted the clinical
ratings. Patients returned to the clinic for weekly visits during the first month of the
treatment period and every four weeks after that. Laboratory assessments were conducted
using fasting blood samples collected every four weeks.
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All participants received a manualized behavioral intervention, adapted from a group
treatment (Brar, Ganguli et al. 2005; Ganguli 2007), that was aimed at improving exercise
and diet habits. The behavioral intervention was provided in person at all post-baseline study
visits. After the first four weeks, study personnel made a telephone call to reinforce the
behavioral treatment lessons between each of the monthly visits.
2.1 Primary outcome: definition and analyses
The primary outcome was change in predicted 10-year CHD risk as measured by the
Framingham Risk Score, calculated according to the formula developed by Wilson et al.
(Wilson, D’Agostino et al. 1998). The score is a function of sex, age, HDL cholesterol, total
cholesterol, systolic blood pressure, and presence of smoking.
The primary analysis compared the FRS change from baseline to 24 weeks between Stay
and Switch groups for randomized participants who remained on study treatment for at least
one month, which was the first time after baseline that outcome measures were collected.
Longitudinal mixed effects linear models were used for the primary analysis. Model effects
included main effects corresponding to incoming medication, baseline, visit week, treatment
(stay vs. switch), as well as a treatment by time (i.e., visit) interaction term. As designed in
our statistical analysis plan, our models included research site (with small sites pooled
together) as a random effect, but in a small number of cases the actual effect of site was so
small as to produce covariance parameters estimates close to zero, which caused
computational instability and necessitated the removal of the site effect in those models. An
unstructured variance-covariance matrix was used, and the primary contrast of interest was
the comparison of least squares means in change from baseline between stay and switch at
the 24-week visit. Other continuous outcome measures were analyzed using linear mixed
models as described above for the primary analysis.
2.2 Secondary outcome: definition and analyses
Presence of metabolic syndrome was defined as having three or more of the following five
components: elevated waist circumference defined as ≥ 40 inches for males and ≥ 35 inches
for females; elevated fasting triglycerides, defined as ≥ 150 mg/dL; reduced HDL
cholesterol, defined as <40mg/dL for males and <50mg/dL for females; elevated blood
pressure, defined as ≥ 130/85 mm Hg; and elevated fasting glucose, defined as ≥100mg/dL
(Alberti, Zimmet et al. 2005). Metabolic syndrome was analyzed at the last observed value
for the 187 randomized participants who stayed on study treatment for at least one month.
Cochran-Mantel-Haenszel tests stratified by incoming medication were used to compare
treatment groups with respect to the proportion of participants experiencing metabolic
syndrome. Logistic regression models were fit to compare the two treatment groups (stay vs.
switch) with respect to metabolic syndrome, adjusting for incoming medication and
metabolic syndrome at baseline. To determine maximum possible effect, change in
metabolic syndrome status was also examined only for the 129 participants who completed
the entire 24-week protocol on assigned treatment.
3. Results
A total of 215 patients were randomized; 109 were assigned to switch to aripiprazole and
106 to stay on the current antipsychotic. We focused our attention only on those study
participants who could provide relevant data. The measures for the primary outcomes in this
study were evaluated in 89 switchers and 98 stayers who completed at least one month of
study participation and thus had at least one post-baseline visit at which the outcomes could
be determined while on the assigned treatment (Table 1). Two participants never took study
drug. Investigators attributed patient discontinuations of the protocol-specified treatment
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during the first month to the following reasons: lack of efficacy (stay N=0, switch N=9),
unacceptable side effects (stay N=2, switch N=3), patient withdrew (stay N=2, switch N=0),
lost to follow-up (stay N=2, switch N=5), disallowed medicine (stay N=2, switch N=1)
(Stroup, McEvoy et al. 2011). Table 1 depicts the baseline demographic and clinical
characteristics of the 187 patients in these analyses. Mean daily doses for patients during the
study were 16.9 mg of aripiprazole, 18.0 mg of olanzapine, 572.0 mg of quetiapine, and 4.1
mg of risperidone.
3.1 Change in 10-year coronary heart disease risk estimates
Table 2 depicts covariate-adjusted changes in metabolic parameters over the course of the
study for the groups that stayed on the current antipsychotic or switched to aripiprazole. At
study entry the mean FRS for both groups combined was 0.073, indicating a 7.3% risk of
CHD over 10 years. Least squares mean estimates of 10-year CHD risk decreased more for
the switch (from 7.0% to 5.2%) than the stay group (from 7.4% to 6.4%)(p=0.0429); thus
the 10-year risk reduction was 25% for switchers compared to 13.5% for stayers.
3.2 Metabolic syndrome status
Among the 187 patients who stayed on study medication at least one month, the prevalence
of the metabolic syndrome at the last observation decreased for switchers (from 57% to
45%) and for stayers (from 66% to 60%). The odds ratio for having metabolic syndrome
(stay vs. switch) at the last observation was 1.748 (95% CI 0.919, 3.324, p=0.0885). Results
were similar among the 129 participants who completed the 24-week protocol on study
treatment—the prevalence of metabolic syndrome decreased for switchers (from 55% to
40.1%) and for stayers (from 64.2% to 58.7%).
3.3 Results by gender
We conducted additional post hoc analyses by gender (118 men and 69 women). For men
the mean FRS at study entry was 8.6%, while for women it was 5.1 %. (This compares to
general population means of 7.0% for men and 4.2% for women calculated for a group of
controls matched to participants in the CATIE study (Goff, Sullivan et al. 2005).) In the
analysis including only men, the difference in reductions of predicted 10-year CHD risk
between the switch (2.3%) and stay groups (0.8%) was not statistically significant
(p=0.073). For women there was also no significant difference in the magnitude of
reductions of predicted 10-year CHD risk between stayers (1.1%) and switchers (0.8%)
(p=0.5161).
For men, the prevalence of metabolic syndrome decreased from 55.6% to 42.6% among
switchers and from 65.6 % to 60.9% for stayers. For women, the prevalence of metabolic
syndrome decreased from 60.0% to 48.6% among switchers and from 67.6% to 58.8% for
stayers.
3.4 Results according to incoming drug strata
Table 3 depicts covariate-adjusted changes in metabolic parameters over the course of the
study according to the antipsychotic medication participants were taking when entering the
study. For participants entering the study on olanzapine, those who switched to aripiprazole
experienced a 26.3% reduction in FRS compared to a 12.5% reduction for stayers. For
quetiapine, switchers experienced a 31.6% reduction in FRS compared to a 10.7% reduction
for stayers. For risperidone, switchers experienced a 22.2% reduction in FRS compared to a
15.9% reduction for stayers. The odds ratios for having metabolic syndrome (stay vs.
switch) at participants’ last visit according to the incoming drug strata were as follows:
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olanzapine 1.035 (95% CI 0.344, 3.110, p=0.9515), quetiapine 1.372 (95% CI 0.364, 5.177,
p=0.6407), and risperidone 3.309 (95% CI 1.187, 9.229, p=0.0222).
4. Discussion
We conducted a randomized controlled trial to test the effectiveness of switching
antipsychotic medications to ameliorate adverse metabolic effects associated with
cardiovascular disease. In a previous paper we reported that switching to aripiprazole was
associated with decreased non-HDL cholesterol, weight, and triglycerides compared to
staying on the current medication (olanzapine, quetiapine, or risperidone)(Stroup, McEvoy
et al. 2011). In this paper, the second of two planned papers for the CAMP study, we have
translated the study results into constructs that are useful and commonly used in clinical
settings. The new analyses focusing on 10-year cardiovascular risk and metabolic syndrome
status found that switching from treatment with olanzapine, quetiapine, or risperidone to
treatment with aripiprazole resulted in decreased predicted risk of CHD as reflected by
Framingham Risk Scores. The reduced prevalence of metabolic syndrome for switchers
compared to stayers was not statistically significant.
The Framingham Risk Score is used clinically to identify individuals who can be targeted
for educational efforts and for lifestyle and medical interventions. Reductions in predicted
CHD risk are an indication of the benefits of an intervention. In this study, twenty-four
weeks of switch to aripiprazole resulted in calculated risk reduction in predicted CHD events
over 10 years from 7.0% to 5.2% (reduction of 25.7%) for switchers while the stayers, who
received the behavioral program alone, had a reduced risk of 13.5%. To provide a
comparison of the magnitude of this effect, a recent meta-analysis by the Cochrane group
found that treatment durations of 2.4 to 5.2 years led to a 28% relative risk reduction in
observed CHD events for statins (vs. placebo) for primary prevention of CHD (Taylor, Ward
et al. 2011). It remains to be determined if large prospective trials powered for CHD events
would show actual risk reduction similar to the estimated effect in the current study and
whether the magnitude of impact for switching of antipsychotics can be enhanced through
longer intervention periods. The number of participants in the CAMP study, while not large,
was adequate to test the primary study hypothesis and to find statistically significant and
clinically meaningful findings in the current analyses.
A strength of the current study is that it was specifically designed to examine factors
associated with risk of cardiovascular disease. We note that the mean baseline FRS in this
study was lower in this study than that in the CATIE schizophrenia trial (Goff, Sullivan et
al. 2005) even though individuals volunteered to participate in this study because they
wanted to reduce CVD risk. One likely reason is that the present study excluded individuals
with diabetes and those with clinically severe dyslipidemias. While the CATIE study was
meant to be as inclusive as possible, the goal of the CAMP study was to evaluate the
effectiveness of switching to prevent the serious problems that were so prevalent in the
CATIE study. Because participants in the CAMP study were at risk of cardiovascular
disease and diabetes but did not yet have these conditions, results from this study best
generalize to this commonly encountered group. The reduction in CHD risk found with
antipsychotic switching in this study could be different in more inclusive populations found
in routine care.
One limitation of the study is its coupling of the medication switch with a diet and exercise
program. Because structured behavioral programs are not routinely offered in typical care
settings, this may limit the generalizability of findings. In addition, the use of such a
program in this study’s control group and in conjunction with switching may have
attenuated the differences in the groups compared to typical practice in which the likely
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options are switching alone compared to staying alone. In addition, because the patients in
this study wanted to reduce their risk of CHD, the benefits of the behavioral intervention
were likely greater in this motivated group than in general populations.
Because the long-term trajectory of metabolic changes is uncertain, another limitation is the
study’s relatively short intervention period (24 weeks). In this study, the benefits of
switching to aripiprazole on serum triglycerides and non-HDL cholesterol were realized in
the first month of treatment and then maintained, while weight reduction advantages
continued to accrue over the study period (Stroup, McEvoy et al. 2011). Although
behavioral programs may have long-term benefits for those who continue to participate,
poor retention in such programs may limit their long-term impact (Holt, Pendlebury et al.
2010).
All study participants in the study received close monitoring to minimize the risk of clinical
destabilization. Nine (8.3%) switchers to aripiprazole and no (0%) stayers discontinued
protocol-specified treatment in the first month due to lack of efficacy, as judged by the
investigator (Stroup, McEvoy et al. 2011). Over the entire 24 weeks, 18 (16.8%) switchers
stopped aripiprazole and three (2.8%) stayers stopped study medication due to investigator-
judged lack of efficacy (Stroup, McEvoy et al. 2011). These judgments by investigators who
were not blinded to treatment assignment are in sharp contrast to rates of protocol-specified
efficacy failure, which required hospitalization or blinded ratings that found substantial
worsening of psychopathology. By this more objective measure, rates of efficacy failure
were similar for the switchers (N=22, 20.6%) and stayers (N=18, 17.0%) (p=0.4782)(Stroup,
McEvoy et al. 2011). In contrast, an open-label pilot study of 15 patients who tried
switching to aripiprazole also reported a high rate (33%) of stopping aripirazole due to
“actual or fear of symptom worsening” (Kim, Ivanova et al. 2007). These results strongly
suggest that blinding is important to avoid expectation biases in studies involving clinical
endpoints. Aripiprazole, while clearly an efficacious treatment for schizophrenia (El-Sayeh
and Morganti 2006), has been shown in a meta-analysis to be less efficacious than
olanzapine (Leucht, Komossa et al. 2009). Close clinical monitoring is necessary during and
after a switch to aripiprazole or any other antipsychotic medication.
Results according to incoming drug strata and by gender should be considered exploratory.
For example, it is surprising that switches from risperidone but not from olanzapine or
quetiapine were associated with reductions in metabolic syndrome prevalence. The nominal
statistical significance for findings in these exploratory analyses may suggest real effects or
chance.
In conclusion, switching from olanzapine, quetiapine, or risperidone to aripiprazole was
associated with reduced predicted risk of CHD. Both the 25% reduction in FRS associated
with switching to aripiprazole together with the behavioral program and the 13.5% reduction
associated with the behavioral program alone are clinically meaningful. Switches to other
antipsychotic medications that have favorable metabolic profiles are other options.
Clinicians may also consider recommending metformin, statins, diet and exercise programs,
and smoking cessation programs as alternative approaches that can be considered alone or in
conjunction with switching medications. One advantage of the switching strategy, compared
to the use of adjunctive medications, is that it avoids additional medications, potential drug
interactions and additional costs. However, a switch strategy may not always be effective
(Stroup, McEvoy et al. 2011). Although switching in this study was not associated with
significantly more efficacy failures or hospitalizations, the process of changing antipsychotic
medications to ameliorate metabolic adverse effects can be unpredictable and requires close
clinical monitoring. The effects on reductions of CHD risk associated with switching to
aripiprazole over periods longer than 24 weeks are not clear and should be examined, as
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should the possible benefits of switching to other antipsychotics with similar weight and
metabolic effects. The benefit of the behavioral program on cardiovascular risk over 24
weeks in this study suggests that this important intervention also warrants further long-term
study. Other efforts to reduce the risks of cardiovascular disease, such as smoking cessation,
are also warranted.
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Table 1
Baseline Demographic and Clinical Characteristics of Efficacy Evaluable Population
Total (N=187) Switch (N=89) Stay (N=98)
Demographic characteristics
Age - yr 41 ± 11.1 40 ± 11.8 42 ± 10.5
Sex - no. (%)
 Male 118 (63.1) 54 (60.7) 64 (65.3)
 Female 69 (36.9) 35 (39.3) 34 (34.7)
Race - no. (%)
 White 106 (56.7) 52 (58.4) 54 (55.1)
 Non-White 80 (42.8) 37 (41.6) 43 (43.9)
Spanish, Hispanic or Latino ethnicity - no. (%) 34 (18.2) 15 (16.9) 19 (19.4)
Education - yr 12 ± 2.5 12 ± 2.3 12 ± 2.7
High school education or above - no. (%) 144 (77.0) 67 (75.3) 77 (78.6)
Marital Status - no. (%)
 Married 15 (8.0) 8 (9.0) 7 (7.1)
 Previously Married 59 (31.6) 31 (34.8) 28 (28.6)
 Never Married 113 (60.4) 50 (56.2) 63 (64.3)
Living Situation - no. (%)
 Independent/non-structured 157 (84.0) 74 (83.1) 83 (84.7)
 Other 30 (16.0) 15 (16.9) 15 (15.3)
Incoming antipsychotic medication -no. (%)
 Olanzapine 64 (34.2) 29 (32.6) 35 (35.7)
 Quetiapine 51 (27.3) 23 (25.8) 28 (28.6)
 Risperidone 72 (38.5) 37 (41.6) 35 (35.7)
Smoking - no. (%)
 Yes 104 (55.6) 50 (56.2) 54 (55.1)
 No 82 (43.9) 38 (42.7) 44 (44.9)
Clinical characteristics
Metabolic Syndrome - no. (%) 116 (62.0) 51 (57.3) 65 (66.3)
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Total (N=187) Switch (N=89) Stay (N=98)
Weight - kg 104 ± 21.1 104 ± 21.4 103 ± 21.0
Fasting glucose - mg/dL 96 ± 11.5 96 ± 10.9 97 ± 12.0
LDL Cholesterol - mg/dL 140 ± 28.4 138 ± 26.4 142 ± 30.1
HDL Cholesterol - mg/dL 44 ± 11.5 45 ± 12.7 43 ± 10.1
Triglycerides - mg/dL 172 ± 96.4 163 ± 90.7 180 ± 101.1
TG/HDL ratio 4.4 ± 3.19 4.2 ± 3.08 4.7 ± 3.29
Waist circumference (inches) 44 ± 5.7 44 ± 5.7 44 ± 5.8
Systolic blood pressure (mmHg) 128 ± 15.2 127 ± 14.2 130 ± 15.9
Diastolic blood pressure (mmHg) 84 ± 11.8 83 ± 11.7 84 ± 12.0
Framingham risk score 0.073 ± 0.057 0.070 ± 0.056 0.074 ± 0.058
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Table 2
Outcome Measures of Effectiveness in the Efficacy Evaluable Population - by treatment
Switch (N=89) Stay (N=98) Difference (95% CI) P value*
Primary Outcome
 Change in Framingham Risk Score −0.018 ± 0.0030 −0.010 ± 0.0026 0.008 (0.000,0.016) 0.0429#
Other Secondary Outcomes
 Metabolic Outcomes
  Change in weight (kg) −3.6 ± 0.48 −0.7 ± 0.44 29 (1.6,4.2) <.0001#
  Change in LDL Cholesterol (mg/dL) −15.4 ± 27.6 −12.5 ± 2.54 2.9 (−3.9,9.6) 0.4003
  Change in HDL Cholesterol (mg/dL) 0.6 ± 0.76 −0.1 ± 0.68 −0.7 (−2.7,1.3) 0.4693#
  Change in Triglycerides (mg/dL) −25.7 ± 8.10 7.0 ± 7.20 32.7 (12.1,53.4) 0.0020
  Change in TG/HDL ratio −0.8 ± 0.25 0.2 ± 0.22 1.0 (0.3,1.6) 0.0029#
  Change in fasting glucose (mg/dL) 0.5 ± 1.43 4.0 ± 1.25 3.5 (−0.2,7.1) 0.0607
  Change in waist circumference (inches) −1.4 ± 0.25 −0.5 ± 0.22 0.9 (0.2,1.5) 0.0075#
  Change in systolic bood pressure (mmHg) −3.4 ± 1.39 −1.0 ± 1.23 23 (−1.0,5.7) 0.1753
  Change in diastolic blood pressure (mmHg) −3.2 ± 1.18 −1.8 ± 1.07 1.4 (−1.2,4.0) 0.2937
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